VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 376 EUR | +0.80% |
|
+3.01% | +4.59% |
| Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated |  |
| Apr. 17 | Virbac: sales up by almost 10% in Q1 | CF |
| Sales 2023 | 1.25B 1.33B | Sales 2024 * | 1.39B 1.47B | Capitalization | 3.12B 3.32B |
|---|---|---|---|---|---|
| Net income 2023 | 121M 129M | Net income 2024 * | 139M 148M | EV / Sales 2023 | 2.39 x |
| Net cash position 2023 | 52.36M 55.65M | Net Debt 2024 * | 130M 138M | EV / Sales 2024 * | 2.35 x |
| P/E ratio 2023 |
25
x | P/E ratio 2024 * |
22.5
x | Employees | 5,459 |
| Yield 2023 |
0.37% | Yield 2024 * |
0.39% | Free-Float | 49.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Virbac
More press releases
More news
| 1 day | +1.22% | ||
| 1 week | +3.90% | ||
| Current month | +7.80% | ||
| 1 month | +10.36% | ||
| 3 months | +11.34% | ||
| 6 months | +43.19% | ||
| Current year | +3.76% |
1 week
354.00
376.00
1 month
316.50376.00
Current year
316.50376.00
1 year
232.50376.00
3 years
215.00448.50
5 years
132.20448.50
10 years
102.10448.50
| Managers | Title | Age | Since |
|---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 10-12-31 | |
Philippe Capron
BRD | Director/Board Member | 64 | 03-12-31 |
| Chairman | 59 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 1 M€ | -.--% | ||
| 0.02% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 376 | +0.80% | 11 612 |
| 24-04-18 | 373 | +1.22% | 5,115 |
| 24-04-17 | 368.5 | +2.36% | 7,796 |
| 24-04-16 | 360 | 0.00% | 2,996 |
| 24-04-15 | 360 | -1.37% | 2,616 |
Real-time Euronext Paris, April 18, 2024 at 11:35 am EDT
More quotes
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.8%), Europe (24.9%), Asia (17.5%), Latin America (16.2%), North America (13.3%), Pacific (9.7%), Africa and Middle East (2.6%).
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
373
EUR
Average target price
361.6
EUR
Spread / Average Target
-3.07%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.76% | 3.33B | |
| -8.93% | 6.69B | |
| +13.00% | 3.35B | |
| +2.87% | 1.46B | |
| -17.92% | 1.33B | |
| -7.71% | 1.19B | |
| -28.92% | 1.19B | |
| -17.76% | 1.08B | |
| -3.84% | 1.01B | |
| -1.98% | 868M |
- Stock Market
- Equities
- VIRP Stock
